Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2020-06-03 Capital/Financing Update
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia Intends To Carry Out A Directed Share Issue Through An Accelerated Book Building Process
Capital/Financing Update Classification · 99% confidence The document is a press release titled "Immunovia Intends To Carry Out A Directed Share Issue Through An Accelerated Book Building Process." The content explicitly discusses the intent to issue new shares (a capital raise) directed towards institutional investors via an accelerated book building procedure. This action directly relates to changing the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2020-06-03 English
Immunovia offentliggör avsikt att genomföra en riktad nyemission av aktier genom ett accelererat bookbuilding-förfarande
Capital/Financing Update Classification · 99% confidence The document is a press release dated June 3, 2020, titled "Immunovia offentliggör avsikt att genomföra en riktad nyemission av aktier genom ett accelererat bookbuilding-förfarande" (Immunovia announces intention to conduct a directed new issue of shares through an accelerated bookbuilding procedure). The content explicitly discusses raising capital through a new share issue ('nyemission') directed towards institutional investors, detailing the intended use of proceeds (commercialization acceleration) and the process (accelerated bookbuilding). This clearly falls under the category of company fundraising, financing activities, or capital structure changes. This matches the definition for Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it describes a specific corporate action, nor is it a share repurchase (POS) as it is a new issue/fundraising effort.
2020-06-03 Swedish
Immunovia Provides Forth Update During COVID-19 Pandemic
Earnings Release Classification · 99% confidence The document is a 'PRESS RELEASE' dated May 27, 2020, providing an update on the company's operations (reopening of a lab) and announcing a live conference call to discuss COVID-19 impact and launch preparations for their product, IMMray™ PanCan-d. The text explicitly states that the company 'will host a live call today at 16:30 CET' and provides dial-in numbers and a webcast link. This structure—a brief update followed by the announcement of a call to discuss results or operational matters—is characteristic of an Earnings Release (ER) or a general update that often accompanies an earnings call. Since it is a press release announcing operational updates and an associated call, it most closely aligns with an Earnings Release (ER) which typically precedes or accompanies the detailed financial discussion, or potentially a Call Transcript (CT) if the text *was* the transcript, but here it is the *announcement* of the call. Given the context of providing an update and immediately scheduling a call for discussion, ER is the most appropriate fit among the primary financial reporting categories, although it is not a formal financial statement itself. However, since the document is short (4348 chars) and primarily serves to announce an event (the call) and provide a brief operational update, it could also be considered a Regulatory Filing (RNS) or a Report Publication Announcement (RPA) if it were announcing a *report*. Since it announces a *call*, and the content is an operational update, ER is the best fit for the *topic* being discussed, but the *format* is a press release announcing an event. Given the options, and the fact that these updates often accompany earnings periods, ER is selected. If the document was *only* announcing the call without the operational update, RPA might be considered, but the content is substantive operational news. FY 2020
2020-05-27 English
Immunovia lämnar en fjärde uppdatering under covid-19-pandemin
Regulatory Filings Classification · 100% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and provides an update regarding the company's operations (reopening of a lab) in response to the COVID-19 pandemic and upcoming product launch preparations. Crucially, it announces that the company will hold a conference call to discuss these updates and provides dial-in details and a webcast link. It also mentions that an MP3 recording of the call will be available later. This structure—a brief announcement followed by details for an investor/analyst call—strongly indicates a communication designed to disseminate timely, non-periodic operational news, often preceding a formal earnings release or a major report. Since it is an announcement about a discussion/call, and not the full transcript (CT) or a formal financial report (ER/IR/10-K), the most fitting category is a general regulatory announcement or a communication related to investor relations that doesn't fit a more specific category. Given the content is a general operational update and announcement of a call, it fits best under Regulatory Filings (RNS) as a general announcement, or potentially an Earnings Release (ER) if it were tied to financial results, but here it is operational/COVID-related. Since it is a press release announcing operational updates and an associated conference call, RNS (Regulatory Filings) is the most appropriate general category for non-standard, timely announcements.
2020-05-27 Swedish
Immunovia lämnar en tredje uppdatering under covid-19-pandemin
Earnings Release Classification · 99% confidence The document is a press release dated May 13, 2020, titled "Immunovia lämnar en tredje uppdatering under covid-19-pandemin" (Immunovia provides a third update during the covid-19 pandemic). It discusses operational adjustments (delaying product launch to Q4 2020) due to the pandemic and announces a conference call to discuss these updates. Since the document is an announcement about operational status and includes details for an upcoming conference call (which is a form of communication often associated with earnings or significant updates), it most closely aligns with an Earnings Release (ER) or a general Regulatory Filing (RNS). However, it is not the full financial report (10-K or IR), nor is it solely a presentation (IP). Given that it provides an update on business status and timelines, and announces a call to discuss it, it functions similarly to an Earnings Release, even if it's not strictly quarterly results. Since it's a formal update announcing operational changes and scheduling a call, and it's not a specific report type like 10-K or IR, the best fit among the provided options that covers timely operational/business updates is ER, or RNS as a fallback. Because it explicitly announces a conference call to discuss the business situation, ER is a strong candidate, but RNS covers general regulatory announcements that don't fit elsewhere. Given the context of providing an update on business continuity and timelines, and announcing a call, RNS is the most appropriate general regulatory announcement category when ER is reserved for formal financial results releases. However, the content is very similar to an ER update. I will classify it as RNS as it is a general regulatory update/press release that doesn't fit the strict definition of ER (which usually contains key financial figures). Q4 2020
2020-05-13 Swedish
Immunovia Provides Third Update During COVID-19 Pandemic
Call Transcript Classification · 95% confidence The document is titled "PRESS RELEASE" and provides an update on the company's operations and timeline adjustments due to the COVID-19 pandemic. Crucially, the text states: "In conjunction, Immunovia will host a live call today at 16:30 CET with Mats Grahn, CEO, to further discuss COVID-19 and IMMray™ PanCan-d launch preparations." It then provides detailed dial-in numbers, conference codes, and registration links for this live call. This structure—a press release announcing and detailing how to access a live discussion/Q&A session—is the defining characteristic of a Call Transcript (CT) announcement, even though the transcript itself is not present yet (the recording will be available later). Since the primary focus of the announcement is the upcoming live call/webcast, the most appropriate classification is Call Transcript (CT).
2020-05-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.